Staidson (Beijing) BioPharmaceuticals Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Wang Chao

Amministratore delegato

CN¥1.4m

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	3.3yrs
Proprietà del CEO	0.08%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	3.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SZSE:300204) Stock Rockets 47% As Investors Are Less Pessimistic Than Expected

Oct 08

Subdued Growth No Barrier To Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SZSE:300204) With Shares Advancing 26%

Aug 03

There's Reason For Concern Over Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s (SZSE:300204) Massive 26% Price Jump

Aug 02

What Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s (SZSE:300204) 25% Share Price Gain Is Not Telling You

Mar 18

AMMINISTRATORE DELEGATO

Wang Chao (42 yo)

3.3yrs

Mandato

CN¥1,362,100

Compensazione

Mr. Wang Chao is General Manager of Staidson (Beijing) BioPharmaceuticals Co. Ltd. from August 2021.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Zhi Wen Zhou	Chairman	15.5yrs	CN¥1.30m	1.1% CN¥ 43.2m
Tao Li	Supervisor	13.8yrs	CN¥168.10k	Nessun dato
Hongshan Zhang	Chairman of Supervisory Board	6.2yrs	CN¥240.00k	0.098% CN¥ 3.8m
Rong Qin Zhang	Non-Independent Director	6.2yrs	CN¥1.70m	0.21% CN¥ 8.1m
Lianchun Yang	Non-Independent Director	3.3yrs	CN¥1.60m	0.075% CN¥ 2.9m
Li Zhao	Independent Director	3.3yrs	CN¥136.80k	Nessun dato
Jiajun Zhao	Independent Director	3.3yrs	CN¥136.80k	Nessun dato
Hong Zheng	Employee Supervisor	3.3yrs	Nessun dato	0.024% CN¥ 941.8k
Xiaoyan Wang	Director	2.2yrs	Nessun dato	Nessun dato

3.3yrs

Durata media

59yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 300204 sono considerati esperti (durata media dell'incarico 3.3 anni).

Staidson (Beijing) BioPharmaceuticals Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Staidson (Beijing) BioPharmaceuticals Co., Ltd., Annual General Meeting, Apr 16, 2024

High number of new directors

Recent updates

Third quarter 2024 earnings released: CN¥0.008 loss per share (vs CN¥0.068 loss in 3Q 2023)

Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SZSE:300204) Stock Rockets 47% As Investors Are Less Pessimistic Than Expected

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings released: EPS: CN¥0.001 (vs CN¥0.22 loss in 2Q 2023)

Subdued Growth No Barrier To Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SZSE:300204) With Shares Advancing 26%

There's Reason For Concern Over Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s (SZSE:300204) Massive 26% Price Jump

New minor risk - Share price stability

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024

First quarter 2024 earnings released: CN¥0.01 loss per share (vs CN¥0.10 loss in 1Q 2023)

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Staidson (Beijing) BioPharmaceuticals Co., Ltd., Annual General Meeting, Apr 16, 2024

Full year 2023 earnings released: CN¥0.84 loss per share (vs CN¥0.41 loss in FY 2022)

What Staidson (Beijing) BioPharmaceuticals Co., Ltd.'s (SZSE:300204) 25% Share Price Gain Is Not Telling You

New major risk - Share price stability

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: CN¥0.068 loss per share (vs CN¥0.15 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.22 loss per share (vs CN¥0.14 loss in 2Q 2022)

Full year 2022 earnings released: CN¥0.41 loss per share (vs CN¥0.29 loss in FY 2021)

Third quarter 2022 earnings released: CN¥0.15 loss per share (vs CN¥0.14 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.094 loss in 2Q 2021)

Full year 2021 earnings: EPS and revenues miss analyst expectations

High number of new directors

Third quarter 2021 earnings released: CN¥0.14 loss per share (vs CN¥0.05 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.094 loss per share (vs CN¥0.11 loss in 2Q 2020)

First quarter 2021 earnings released: CN¥0.04 loss per share (vs CN¥0.05 loss in 1Q 2020)

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report Fiscal Year 2020 Results on Apr 20, 2021

New 90-day low: CN¥8.02

New 90-day low: CN¥8.59

New 90-day low: CN¥9.90

Third quarter earnings released

New 90-day low: CN¥10.52

New 90-day low: CN¥10.73

First half earnings released

Staidson (Beijing) BioPharmaceuticals Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥13.02